Global Recurrent Parotitis Treatment Market, By Treatment (Medications, Sialoendoscopy, Parotidectomy, Radiotherapy, Tympanic Neurectomy, Others), Diagnosis (X-Ray, Computed Tomography (CT) Scan, Magnetic Resonance Imaging (MRI), Sialography, Ultrasonography, Others), Symptoms (Fever, Inflammation of the Parotid Gland, Redness, Recurrence of Inflammation and Swelling in Repeated Episodes, Pain, Others), Dosage (Injection, Tablets, Others), Route of Administration (Oral, Parenteral, Others), End-Users (Clinic, Hospital, Others), Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy), Country (U.S., Canada, Mexico, Brazil, Argentina, Peru, Rest of South America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Hungary, Lithuania, Austria, Ireland, Norway, Poland, Rest of Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Vietnam, Rest of Asia-Pacific, Saudi Arabia, U.A.E, Egypt, Israel, Kuwait, South Africa, Rest of Middle East and Africa) Industry Trends and Forecast to 2029
Market Analysis and Insights Global Recurrent Parotitis Treatment Market
Recurrent parotitis treatment market is expected to gain market growth in the forecast period of 2022-2029. Data Bridge Market Research analyses the market to account to grow at a CAGR of 6% in the above mentioned forecast period and is expected to reach the USD 7,876.35 million by 2029.
The swelling of one or both parotid glands, which are salivary glands positioned in the cheek between the ear and jaw on each side of the head, is known as parotitis. Recurrent parotitis is a recurrent parotid inflammation that is usually linked with non-obstructive parotid gland sialectasis. Recurrent parotitis in children is also termed as juvenile recurrent parotitis. Recurrent episodes of swelling and/or pain in the parotid gland, frequently accompanied by fever and malaise, characterize this condition. It generally affects youngsters, although it can also impact adults. It's a rare ailment, and the cause is yet unknown. Underproduction of saliva, a history of bacterial or viral infections, congenital deformity of the salivary ducts, genetic predisposition, or an underlying autoimmune condition are some of the possibilities being investigated by researchers. Swelling of the parotic glands appears to be caused by a disruption in the usual flow of saliva, which leads to infection of the parotid glands.
The rise in the prevalence of recurrent parotitis is the major driver resulting in the expansion of market’s growth. Another significant factor influencing the growth rate of recurrent parotitis treatment market is the rising healthcare expenditure. Furthermore, advancement in the medical technology, growing government funding and rising initiatives by public and private organisations to spread awareness are the factors that will expand the recurrent parotitis treatment market. Other factors such as increase in the level of disposable income and upsurge in the adoption rate of early genetic counseling will positively impact the recurrent parotitis treatment market’s growth rate. Additionally, improvements associated with reimbursement policies will result in the expansion of recurrent parotitis treatment market.
Moreover, the rise in the research and development activities and high unmet need of current treatment will provide beneficial opportunities for the recurrent parotitis treatment market in the forecast period of 2022-2029. Also, continuous clinical trials will escalate the growth rate recurrent parotitis treatment market in future.
However, high cost associated with the treatment and lack of healthcare infrastructure in low-income countries will impede the growth rate of recurrent parotitis treatment market. Additionally, complications involved with recurrent parotitis treatment will hinder the recurrent parotitis treatment market growth. Less awareness about recurrent parotitis treatment will further challenge the market in the forecast period mentioned above.
This recurrent parotitis treatment market report provides details of new recent developments, trade regulations, import export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the recurrent parotitis treatment market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.
Global Recurrent Parotitis Treatment Market Scope and Market Size
The recurrent parotitis treatment market is segmented on the basis of treatment, diagnosis, symptoms, dosage, route of administration, end-users and distribution channel. The growth amongst these segments will help you analyze meager growth segments in the industries, and provide the users with valuable market overview and market insights to help them in making strategic decisions for identification of core market applications.
- On the basis of treatment, the recurrent parotitis treatment market is segmented into medications, sialoendoscopy, parotidectomy, radiotherapy, tympanic neurectomy and others. The medication segment is further sub-segmented into antibiotics, analgesics and sialagogues. The others segment is further sub-segmented into warm compresses and others.
- On the basis of diagnosis, the recurrent parotitis treatment market is segmented into X-ray, cervical spine X-rays, computed tomography (CT) scan, magnetic resonance imaging (MRI), sialography, ultrasonography and others.
- On the basis of symptoms, the recurrent parotitis treatment market is segmented into fever, inflammation of the parotid gland, redness, recurrence of inflammation and swelling in repeated episodes, pain, and others.
- On the basis of dosage, the recurrent parotitis treatment market is segmented into injection, tablets and others.
- On the basis of route of administration, the recurrent parotitis treatment market is segmented into oral, parenteral and others.
- On the basis of end-users, the recurrent parotitis treatment market is segmented into clinic, hospital and others.
The recurrent parotitis treatment market is also segmented on the basis of distribution channel into hospital pharmacy, retail pharmacy and online pharmacy.
Recurrent Parotitis Treatment Market Country Level Analysis
Recurrent parotitis treatment market is analyzed and market size information is provided by the country, type, treatment, diagnosis, symptoms, dosage, route of administration, end-users and distribution channel as referenced above.
The countries covered in the recurrent parotitis treatment market report are the U.S., Canada, Mexico, Brazil, Argentina, Peru, Rest of South America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Hungary, Lithuania, Austria, Ireland, Norway, Poland, Rest of Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Vietnam, Rest of Asia-Pacific, Saudi Arabia, U.A.E, Egypt, Israel, Kuwait, South Africa, Rest of Middle East and Africa.
North America dominates the recurrent parotitis treatment market due to the presence of major key players, high disposable income and well-developed healthcare infrastructure in this region. Asia-Pacific is expected to grow during the forecast period of 2022-2029 due to the increasing patient pool, rising investment in the healthcare sector, and growing government support.
The country section of the report also provides individual market impacting factors and changes in regulations in the market domestically that impacts the current and future trends of the market. Data points such as new sales, replacement sales, country demographics, disease epidemiology and import-export tariffs are some of the major pointers used to forecast the market scenario for individual countries. Also, presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of sales channels are considered while providing forecast analysis of the country data.
Patient Epidemiology Analysis
Recurrent parotitis treatment market also provides you with detailed market analysis for patient analysis, prognosis and cures. Prevalence, incidence, mortality, adherence rates are some of the data variables that are available in the report. Direct or indirect impact analysis of epidemiology to market growth are analysed to create a more robust and cohort multivariate statistical model for forecasting the market in the growth period.
Competitive Landscape and Global Recurrent Parotitis Treatment Market Share Analysis
Recurrent parotitis treatment market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, company strengths and weaknesses, product launch, clinical trials pipelines, product approvals, patents, product width and breadth, application dominance, technology lifeline curve. The above data points provided are only related to the companies’ focus related to recurrent parotitis treatment market research.
Some of the major players operating in the recurrent parotitis treatment market are Pfizer Inc., GlaxoSmithKline plc, Novartis AG, Sanofi, Abbott, Bayer AG, Bristol-Myers Squibb Company, F. Hoffmann-La Roche Ltd., Johnson & Johnson Private Limited, Mylan N.V., Allergan, Merck & Co., Inc., Melinta Therapeutics LLC, Basilea Pharmaceutica Ltd., Tetraphase Pharmaceuticals, Teva Pharmaceutical Industries Ltd., Sun Pharmaceutical Industries Ltd., Aurobindo Pharma, Lupin, SHIONOGI & Co., Ltd., AbbVie Inc., Cumberland Pharmaceuticals Inc., Eli Lilly and Company, Boehringer Ingelheim International GmbH, and Takeda Pharmaceutical Company Limited., among others.
SKU-
